Responses in Blood Pressure and Kidney Function to Soluble Guanylyl Cyclase Stimulation or Activation in Normal and Diabetic Rats

2.

Gao

Y

,

Raj

JU

.

Regulation of the pulmonary circulation in the fetus and newborn

.

Physiol Rev

.

2010 Oct

;

90

(

4

):

1291

–

335

.

3.

Tsai

EJ

,

Kass

DA

.

Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics

.

Pharmacol Ther

.

2009 Jun

;

122

(

3

):

216

–

38

.

4.

Friebe

A

,

Koesling

D

.

The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models

.

Nitric Oxide

.

2009 Nov–Dec

;

21

(

3–4

):

149

–

56

.

5.

Krishnan

SM

,

Kraehling

JR

,

Eitner

F

,

Benardeau

A

,

Sandner

P

.

The impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective

.

Int J Mol Sci

.

2018 Jun 9

;

19

(

6

):

1712

.

6.

Terada

Y

,

Tomita

K

,

Nonoguchi

H

,

Marumo

F

.

Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments

.

J Clin Invest

.

1992 Aug

;

90

(

2

):

659

–

65

.

7.

Stasch

JP

,

Schlossmann

J

,

Hocher

B

.

Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence

.

Curr Opin Pharmacol

.

2015 Apr

;

21

:

95

–

104

.

8.

Modlinger

PS

,

Wilcox

CS

,

Aslam

S

.

Nitric oxide, oxidative stress, and progression of chronic renal failure

.

Semin Nephrol

.

2004 Jul

;

24

(

4

):

354

–

65

.

9.

Nossaman

B

,

Pankey

E

,

Kadowitz

P

.

Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications

.

Crit Care Res Pract

.

2012

;

2012

:

290805

.

10.

Prawez

S

,

Ahanger

AA

,

Singh

TU

,

Mishra

SK

,

Sarkar

SN

,

Kumar

D

.

BAY 41-2272 treatment improves acetylcholine-induced aortic relaxation in L-NAME hypertensive rats

.

Int J Angiol

.

2016 Dec

;

25

(

4

):

235

–

40

.

11.

Stasch

JP

,

Dembowsky

K

,

Perzborn

E

,

Stahl

E

,

Schramm

M

.

Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies

.

Br J Pharmacol

.

2002 Jan

;

135

(

2

):

344

–

55

.

12.

Geschka

S

,

Kretschmer

A

,

Sharkovska

Y

,

Evgenov

OV

,

Lawrenz

B

,

Hucke

A

, .

Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats

.

PLoS One

.

2011

;

6

(

7

):

e21853

.

13.

Schinner

E

,

Wetzl

V

,

Schramm

A

,

Kees

F

,

Sandner

P

,

Stasch

JP

, .

Inhibition of the TGFβ signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis

.

FEBS Open Bio

.

2017 Apr

;

7

(

4

):

550

–

61

.

14.

Sharkovska

Y

,

Kalk

P

,

Lawrenz

B

,

Godes

M

,

Hoffmann

LS

,

Wellkisch

K

, .

Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models

.

J Hypertens

.

2010 Aug

;

28

(

8

):

1666

–

75

.

15.

Follmann

M

,

Ackerstaff

J

,

Redlich

G

,

Wunder

F

,

Lang

D

,

Kern

A

, .

Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure

.

J Med Chem

.

2017 Jun 22

;

60

(

12

):

5146

–

61

.

16.

Tobin

JV

,

Zimmer

DP

,

Shea

C

,

Germano

P

,

Bernier

SG

,

Liu

G

, .

Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution, antihypertensive, anti-inflammatory, and antifibrotic effects in preclinical models of disease

.

J Pharmacol Exp Ther

.

2018 Jun

;

365

(

3

):

664

–

75

.

17.

Peters

H

,

Wang

Y

,

Loof

T

,

Martini

S

,

Kron

S

,

Kramer

S

, .

Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis

.

Kidney Int

.

2004 Dec

;

66

(

6

):

2224

–

36

.

18.

Stasch

JP

,

Schmidt

PM

,

Nedvetsky

PI

,

Nedvetskaya

TY

,

Hs

AK

,

Meurer

S

, .

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels

.

J Clin Invest

.

2006 Sep

;

116

(

9

):

2552

–

61

.

19.

Roelofs

JJ

,

Vogt

L

.

Diabetic nephropathy: pathophysiology and clinical aspects.

Springer

;

2018

.

20.

Zimmer

DP

,

Shea

CM

,

Tobin

JV

,

Tchernychev

B

,

Germano

P

,

Sykes

K

, .

Olinciguat, an oral sGC stimulator, exhibits diverse pharmacology across preclinical models of cardiovascular, metabolic, renal, and inflammatory disease

.

Front Pharmacol

.

2020

;

11

:

419

.

21.

Straub

A

,

Benet-Buckholz

J

,

Frode

R

,

Kern

A

,

Kohlsdorfer

C

,

Schmitt

P

, .

Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase

.

Bioorg Med Chem

.

2002 Jun

;

10

(

6

):

1711

–

7

.

22.

Hahn

MG

,

Lampe

T

,

El Sheikh

S

,

Griebenow

N

,

Woltering

E

,

Schlemmer

KH

, .

Discovery of the soluble guanylate cyclase activator runcaciguat (BAY 1101042)

.

J Med Chem

.

2021 May 13

;

64

(

9

):

5323

–

44

.

23.

Akash

MS

,

Rehman

K

,

Chen

S

.

Goto-Kakizaki rats: its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus

.

Curr Diabetes Rev

.

2013 Sep

;

9

(

5

):

387

–

96

.

24.

Vallon

V

,

Kirschenmann

D

,

Wead

LM

,

Lortie

MJ

,

Satriano

J

,

Blantz

RC

, .

Effect of chronic salt loading on kidney function in early and established diabetes mellitus in rats

.

J Lab Clin Med

.

1997 Jul

;

130

(

1

):

76

–

82

.

25.

Birk

C

,

Richter

K

,

Huang

DY

,

Piesch

C

,

Luippold

G

,

Vallon

V

.

The salt paradox of the early diabetic kidney is independent of renal innervation

.

Kidney Blood Press Res

.

2003

;

26

(

5–6

):

344

–

50

.

26.

Vallon

V

,

Osswald

H

.

Dipyridamole prevents diabetes-induced alterations of kidney function in rats

.

Naunyn Schmiedebergs Arch Pharmacol

.

1994 Feb

;

349

(

2

):

217

–

22

.

27.

Vallon

V

,

Richter

K

,

Blantz

RC

,

Thomson

S

,

Osswald

H

.

Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption

.

J Am Soc Nephrol

.

1999 Dec

;

10

(

12

):

2569

–

76

.

28.

Vallon

V

.

Micropuncturing the nephron

.

Pflugers Arch

.

2009 May

;

458

(

1

):

189

–

201

.

29.

Thomson

SC

,

Rieg

T

,

Miracle

C

,

Mansoury

H

,

Whaley

J

,

Vallon

V

, .

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

.

Am J Physiol Regul Integr Comp Physiol

.

2012 Jan

;

302

(

1

):

R75

–

83

.

30.

Fu

Y

,

Gerasimova

M

,

Batz

F

,

Kuczkowski

A

,

Alam

Y

,

Sanders

PW

, .

PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules

.

Nephron

.

2015

;

129

(

1

):

68

–

74

.

31.

Fu

Y

,

Breljak

D

,

Onishi

A

,

Batz

F

,

Patel

R

,

Huang

W

, .

Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin

.

Am J Physiol Renal Physiol

.

2018 Aug

;

315

(

2

):

F386

–

94

.

32.

Novikov

A

,

Fu

Y

,

Huang

W

,

Freeman

B

,

Patel

R

,

van Ginkel

C

, .

SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1

.

Am J Physiol Renal Physiol

.

2019 Jan

;

316

(

1

):

F173

–

85

.

33.

Yamamoto

T

,

Noiri

E

,

Ono

Y

,

Doi

K

,

Negishi

K

,

Kamijo

A

, .

Renal L-type fatty acid: binding protein in acute ischemic injury

.

J Am Soc Nephrol

.

2007 Nov

;

18

(

11

):

2894

–

902

.

34.

Fuhrich

DG

,

Lessey

BA

,

Savaris

RF

.

Comparison of HSCORE assessment of endometrial beta3 integrin subunit expression with digital HSCORE using computerized image analysis (ImageJ)

.

Anal Quant Cytopathol Histpathol

.

2013 Aug

;

35

(

4

):

210

–

6

.

35.

Vallon

V

,

Komers

R

.

Pathophysiology of the diabetic kidney

.

Compr Physiol

.

2011

;

1

(

3

):

1175

–

232

.

36.

Vallon

V

,

Thomson

SC

.

The tubular hypothesis of nephron filtration and diabetic kidney disease

.

Nat Rev Nephrol

.

2020 Jun

;

16

(

6

):

317

–

36

.

37.

Carrisoza-Gaytan

R

,

Ray

EC

,

Flores

D

,

Marciszyn

AL

,

Wu

P

,

Liu

L

, .

Intercalated cell BKα subunit is required for flow-induced K+ secretion

.

JCI Insight

.

2020 Apr 7

;

5

(

8

):

130553

.

38.

Loutzenhiser

R

,

Hayashi

K

,

Epstein

M

.

Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney

.

J Pharmacol Exp Ther

.

1988 Aug

;

246

(

2

):

522

–

8

.

39.

Veldkamp

PJ

,

Carmines

PK

,

Inscho

EW

,

Navar

LG

.

Direct evaluation of the microvascular actions of ANP in juxtamedullary nephrons

.

Am J Physiol

.

1988 Mar

;

254

(

3 Pt 2

):

F440

–

4

.

40.

Kimura

K

,

Hirata

Y

,

Nanba

S

,

Tojo

A

,

Matsuoka

H

,

Sugimoto

T

.

Effects of atrial natriuretic peptide on renal arterioles: morphometric analysis using microvascular casts

.

Am J Physiol

.

1990 Dec

;

259

(

6 Pt 2

):

F936

–

44

.

41.

Thomson

SC

,

Deng

A

.

Cyclic GMP mediates influence of macula densa nitric oxide over tubuloglomerular feedback

.

Kidney Blood Press Res

.

2003 2003

;

26

(

1

):

10

–

8

.

42.

Lanese

DM

,

Yuan

BH

,

Falk

SA

,

Conger

JD

.

Effects of atriopeptin III on isolated rat afferent and efferent arterioles

.

Am J Physiol

.

1991 Dec

;

261

(

6 Pt 2

):

F1102

–

9

.

43.

Brenner

BM

,

Ballermann

BJ

,

Gunning

ME

,

Zeidel

ML

.

Diverse biological actions of atrial natriuretic peptide

.

Physiol Rev

.

1990 Jul

;

70

(

3

):

665

–

99

.

44.

Zatz

R

,

de Nucci

G

.

Effects of acute nitric oxide inhibition on rat glomerular microcirculation

.

Am J Physiol

.

1991 Aug

;

261

(

2 Pt 2

):

F360

–

3

.

45.

Deng

A

,

Baylis

C

.

Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient

.

Am J Physiol

.

1993 Feb

;

264

(

2 Pt 2

):

F212

–

5

.

46.

Denton

KM

,

Anderson

WP

.

Intrarenal haemodynamic and glomerular responses to inhibition of nitric oxide formation in rabbits

.

J Physiol

.

1994 Feb 15

;

475

(

1

):

159

–

67

.

47.

Kramer

HJ

,

Horacek

V

,

Backer

A

,

Vaneckova

I

,

Heller

J

.

Relative roles of nitric oxide, prostanoids and angiotensin II in the regulation of canine glomerular hemodynamics. A micropuncture study

.

Kidney Blood Press Res

.

2004

;

27

(

1

):

10

–

7

.

48.

Blantz

RC

,

Konnen

KS

,

Tucker

BJ

.

Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat

.

J Clin Invest

.

1976 Feb

;

57

(

2

):

419

–

34

.

49.

Thomson

SC

,

Deng

A

,

Komine

N

,

Hammes

JS

,

Blantz

RC

,

Gabbai

FB

.

Early diabetes as a model for testing the regulation of juxtaglomerular NOS I

.

Am J Physiol Renal Physiol

.

2004 Oct

;

287

(

4

):

F732

–

8

.

50.

Hoffend

J

,

Cavarape

A

,

Endlich

K

,

Steinhausen

M

.

Influence of endothelium-derived relaxing factor on renal microvessels and pressure-dependent vasodilation

.

Am J Physiol

.

1993 Aug

;

265

(

2 Pt 2

):

F285

–

92

.

51.

Stehle

D

,

Xu

MZ

,

Schomber

T

,

Hahn

MG

,

Schweda

F

,

Feil

S

, .

Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney

.

Br J Pharmacol

.

2022

;

179

(

11

):

2476

–

89

.

52.

Dautzenberg

M

,

Kahnert

A

,

Stasch

JP

,

Just

A

.

Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat

.

Am J Physiol Renal Physiol

.

2014 Nov 1

;

307

(

9

):

F1003

–

12

.

53.

Boerrigter

G

,

Costello-Boerrigter

LC

,

Cataliotti

A

,

Lapp

H

,

Stasch

JP

,

Burnett

JC

Jr.

Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure

.

Hypertension

.

2007 May

;

49

(

5

):

1128

–

33

.

54.

Boerrigter

G

,

Costello-Boerrigter

LC

,

Cataliotti

A

,

Tsuruda

T

,

Harty

GJ

,

Lapp

H

, .

Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure

.

Circulation

.

2003 Feb 11

;

107

(

5

):

686

–

9

.

55.

Majid

DS

,

Navar

LG

.

Nitric oxide in the control of renal hemodynamics and excretory function

.

Am J Hypertens

.

2001 Jun

;

14

(

6 Pt 2

):

74S

–

82S

.

56.

Yip

KP

.

Flash photolysis of caged nitric oxide inhibits proximal tubular fluid reabsorption in free-flow nephron

.

Am J Physiol Regul Integr Comp Physiol

.

2005 Aug

;

289

(

2

):

R620

–

6

.

57.

Potter

LR

,

Yoder

AR

,

Flora

DR

,

Antos

LK

,

Dickey

DM

.

Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications

.

Handb Exp Pharmacol

.

2009

(

191

):

341

–

66

.

58.

Garvin

JL

,

Herrera

M

,

Ortiz

PA

.

Regulation of renal NaCl transport by nitric oxide, endothelin, and ATP: clinical implications

.

Annu Rev Physiol

.

2011

;

73

:

359

–

76

.

59.

Gao

Y

,

Stuart

D

,

Takahishi

T

,

Kohan

DE

.

Nephron-specific disruption of nitric oxide synthase 3 causes hypertension and impaired salt excretion

.

J Am Heart Assoc

.

2018 Jul 11

;

7

(

14

):

e009236

.

60.

Gonzalez-Vicente

A

,

Saez

F

,

Monzon

CM

,

Asirwatham

J

,

Garvin

JL

.

Thick ascending limb sodium transport in the pathogenesis of hypertension

.

Physiol Rev

.

2019 Jan 1

;

99

(

1

):

235

–

309

.

61.

Evans

RG

,

Majid

DSA

,

Eppel

GA

.

Mechanisms mediating pressure natriuresis: what we know and what we need to find out

.

Clin Exp Pharmacol Physiol

.

2005 May–Jun

;

32

(

5–6

):

400

–

9

.

62.

Shirai

A

,

Yamazaki

O

,

Horita

S

,

Nakamura

M

,

Satoh

N

,

Yamada

H

, .

Angiotensin II dose-dependently stimulates human renal proximal tubule transport by the nitric oxide/guanosine 3’, 5’-cyclic monophosphate pathway

.

J Am Soc Nephrol

.

2014 Jul

;

25

(

7

):

1523

–

32

.

63.

Masuyama

H

,

Tsuruda

T

,

Sekita

Y

,

Hatakeyama

K

,

Imamura

T

,

Kato

J

, .

Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart

.

Hypertens Res

.

2009 Jul

;

32

(

7

):

597

–

603

.

64.

Shea

CM

,

Price

GM

,

Liu

G

,

Sarno

R

,

Buys

ES

,

Currie

MG

, .

Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure

.

Am J Physiol Renal Physiol

.

2020 Jan 1

;

318

(

1

):

F148

–

59

.

65.

Gheorghiade

M

,

Greene

SJ

,

Butler

J

,

Filippatos

G

,

Lam

CSP

,

Maggioni

AP

, .

Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial

.

JAMA

.

2015 Dec 1

;

314

(

21

):

2251

–

62

.

66.

Benardeau

A

,

Kahnert

A

,

Schomber

T

,

Meyer

J

,

Pavkovic

M

,

Kretschmer

A

, .

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease

.

Naunyn Schmiedebergs Arch Pharmacol

.

2021 Dec

;

394

(

12

):

2363

–

79

.